Hangzhou Tigermed Consulting Co., Ltd. (3347) disclosed its unaudited 2025 third quarterly report. From January to September 2025, revenue reached RMB 5.03 billion, a slight decrease of 0.82% compared to the same period last year. Net profit attributable to shareholders stood at RMB 1.02 billion, marking a year-on-year increase of 25.45%. During the third quarter alone, net profit attributable to shareholders rose significantly by 98.73% over the same period in 2024.

The balance sheet recorded total assets of RMB 28.78 billion, reflecting a small rise of 0.39% from the end of 2024. The company reported changes in items such as short-term borrowings, which decreased notably to RMB 601.82 million by the end of September 2025, attributable to repayment efforts. Treasury shares reached RMB 300.07 million due to more share repurchases.

On the operational side, cash flows from operating activities registered RMB 739.56 million, an increase of 27.78% year-on-year. Meanwhile, net cash flow from investing activities turned positive, mainly due to the redemption of certificates of deposit. The financing cash flow was in net outflow, influenced by changes in borrowings and debt repayments.

Additionally, Hangzhou Tigermed approved the transfer of an equity interest in one of its investee companies, LaNova Medicines, for approximately USD 34.11 million, reflecting an ongoing evaluation of investment portfolios.

These figures have been prepared under China Accounting Standards for Business Enterprises and have not been audited.